![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 14, 2020
EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma
December 14, 2020
October 23, 2020
The purpose of the Symposium is to introduce young investigators to ECOG-ACRIN and provide them with a forum to present their research in a formal manner and obtain feedback
October 20, 2020
What are the elements of a productive meeting when we get together – and what might they look like in a virtual format?
October 19, 2020
The Fall 2020 Group Meeting will look different this year – a fact that should not be too surprising, given that it will take place entirely online
October 19, 2020
October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
October 19, 2020
This phase II study, led by Dr. Bonnie Ky, aims to generate the necessary data to inform a phase III randomized controlled trial with the potential to make a significant public health impact
October 19, 2020
September 14, 2020
This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively
July 29, 2020
In the fifth month of restrictions due to COVID-19, member institutions pivot back to focus on general health care; clinical trial enrollments begin to rise back up to pre-pandemic levels; Fall 2020 Group Meeting to be virtual; EA holds first meeting of planned move to an anti-racist agenda
July 29, 2020
In July, the field of radiology lost one its most influential leaders
July 29, 2020
Currently, there is no treatment standard for metastatic pancreatic cancer in people aged 65 years and older